Telehealth company Hims & Hers Health (HIMS) witnessed a major dip in its stock recently despite reporting 95% revenue growth for the fourth quarter of 2024 and a notable jump in earnings.

Shares of Hims & Hers (HIMS) are down $3.47, or 8%, to $37.50 in pre-market trading after a court denied a motion for a preliminary injunction that two compounding groups – the Outsourcing ...

The key to successful weight loss lies not just in diet and exercise, but also in understanding how our body's metabolic processes work. Research has shown that a combination of the keto diet and ...

The keto diet has gained immense popularity over the years due to its potential benefits for weight loss and overall health. With the rise of supplement manufacturers, various products have emerged ...

Sen. Jim Banks (R-Ind.) wants the Food and Drug Administration to look into foreign-made active pharmaceutical ingredients he ...

The rapid rise of GLP-1 weight-loss drugs has come with a raucous side show—a wave of copycat drugs unbound by drug patents. The knockoff surge was led by Hims & Hers Health, the telehealth firm that ...

As obesity rates continue to climb globally, these injectable medications have gained popularity among individuals seeking a more structured medical approach to weight management. However ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings. Hims ...